Fractionated 1927nm Laser for Hyperpigmentation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a laser treatment called MOXI to evaluate its effectiveness in treating hyperpigmentation, a condition causing dark patches on the skin. Researchers aim to determine the safest and most effective use of this laser, particularly for individuals with darker skin tones (Fitzpatrick Skin Phototypes V and VI). The trial includes two groups: one receives a special pre-treatment, while the other receives post-treatment care to compare the effectiveness of each method. Individuals with noticeable facial hyperpigmentation who are willing to pause other skin treatments may be suitable candidates for this study. As an unphased trial, this study provides a unique opportunity to explore innovative treatment options for hyperpigmentation.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does mention that certain therapies and medications might interfere with the study. It's best to discuss your specific medications with the study team to see if they might affect your participation.
What prior data suggests that this laser treatment is safe for hyperpigmentation?
Research has shown that the 1927 nm non-ablative fractionated laser, known as MOXI, is generally safe for treating skin discoloration. In past studies, no negative effects occurred with its use. Patients did not experience unwanted darkening of their skin after treatment. Most patients reported being "satisfied" or "extremely satisfied" with their results.
The MOXI laser has been tested on individuals with darker skin tones and demonstrated significant improvement in reducing dark spots. Importantly, no negative side effects were observed during these treatments. This suggests that the laser is well-tolerated and a safe option for those considering joining a clinical trial.12345Why are researchers excited about this trial?
Researchers are excited about the use of the fractionated 1927nm laser, known as MOXI, for treating hyperpigmentation because it offers a non-invasive approach with potentially fewer side effects compared to traditional methods like topical creams, chemical peels, or intense pulsed light therapy. Unlike these methods, which often require prolonged use and can cause irritation, MOXI targets the skin more precisely, using laser technology to address pigmentation issues at their source. This precise targeting can lead to faster and more noticeable improvements, making it a promising option for those seeking quicker results with minimal downtime.
What evidence suggests that the 1927nm laser treatment could be effective for hyperpigmentation?
Research shows that the MOXI laser, a type of 1927nm laser, effectively treats dark spots on the skin. Studies have found a noticeable improvement in brown spots, with a 9.9% reduction in pigment over time. One study noted a 16% decrease in spots caused by UV exposure and a 7% decrease in brown spots. These results suggest that MOXI can effectively reduce dark spots and improve skin appearance. The laser targets and breaks down excess pigment in the skin, helping to even out skin tone. Participants in this trial will be divided into two groups: one group will receive pre-treatment with tretinoin/hydroquinone, and the other group will receive post-treatment care with temovate.13678
Who Is on the Research Team?
Jeffrey Kenkel, MD
Principal Investigator
UT Southwestern- Department of Plastic Surgery
Are You a Good Fit for This Trial?
Adults aged 18-75 with darker skin tones (Fitzpatrick Skin Phototypes V and VI) who have noticeable hyperpigmentation on their face and are seeking treatment. Participants must be willing to avoid other aesthetic treatments, follow study procedures, use approved birth control if applicable, and not have any health conditions that could interfere with the trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 1927nm non-ablative fractionated laser therapy for hyperpigmentation with treatments on Day 0, Day 30, and Day 60
Follow-up
Participants are monitored for changes in hyperpigmentation and adverse events at 1-month and 3-month follow-up visits
What Are the Treatments Tested in This Trial?
Interventions
- MOXI
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor